Clinical trial
A Study to Evaluate Effectiveness and Safety of BMS-986322 in Participants With…
NCT05730725 · Bristol-Myers Squibb, Industry · Completed
Key facts
| NCT number | NCT05730725 |
|---|---|
| Title | A Study to Evaluate Effectiveness and Safety of BMS-986322 in Participants With Moderate-to-Severe Psoriasis |
| Official title | A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Phase 2 Study to Evaluate the Clinical Efficacy and Safety of BMS-986322 in Participants With Moderate-to-Severe Psoriasis |
| Lead sponsor | Bristol-Myers Squibb, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Psoriasis |
| Intervention type | Drug, Other |
| Interventions | BMS-986322, Placebo |
| Enrollment | 109 |
| Start date | Apr 3, 2023 |
| Primary completion | Aug 6, 2024 |
| Completion | Aug 6, 2024 |
| First posted | Feb 16, 2023 |
| Last update posted | Nov 25, 2025 |
| Countries | Australia, Canada, Japan, United Kingdom, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: